Effects of a novel Nodal-targeting monoclonal antibody in melanoma(220 visite)(PDF privato129 visite) Strizzi L, Sandomenico A, Margaryan NV, Foca A, Sanguigno L, Bodenstine TM, Chandler GS, Reed DW, Gilgur A, Seftor EA, Seftor RE, Khalkhali-ellis Z, Leonardi A, Ruvo M, Hendrix MJ
ONCOTARGET (ISSN: 1949-2553), 2015 Oct 27; 6(33): 34071-34086.
Tipo di articolo: Journal Article,
Impact factor: 5.008, Impact factor a 5 anni: 5.415
Url: Non disponibile.
Parole chiave: Nodal, Cancer, Antibody, Elisa, Therapy,
*** IBB - CNR *** 1 Cancer Biology and Epigenomics Program, Stanley Manne Children’s Research Institute, Ann and Robert H. Lurie Children’s 2 Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA 3 Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA 4 Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA 5 Istituto di Biostrutture e Bioimmagini del CNR and CIRPeB, Università Federico II di Napoli, Naples, Italy 6 Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Federico II di Napoli, Naples, Italy * These authors have contributed equally to this work
Nodal is highly expressed in various human malignancies, thus supporting the<br>rationale for exploring Nodal as a therapeutic target. Here, we describe the effects<br>of a novel monoclonal antibody (mAb), 3D1, raised against human Nodal. In vitro<br>treatment of C8161 human melanoma cells with 3D1 mAb shows reductions in<br>anchorage-independent growth and vasculogenic network formation. 3D1 treated<br>cells also show decreases of Nodal and downstream signaling molecules, P-Smad2<br>and P-ERK and of P-H3 and CyclinB1, with an increase in p27. Similar effects were<br>previously reported in human breast cancer cells where Nodal expression was<br>generally down-regulated; following 3D1 mAb treatment, both Nodal and P-H3 levels<br>are reduced. Noteworthy is the reduced growth of human melanoma xenografts in<br>Nude mice treated with 3D1 mAb, where immunostaining of representative tumor<br>sections show diminished P-Smad2 expression. Similar effects both in vitro and in<br>vivo were observed in 3D1 treated A375SM melanoma cells harboring the active<br>BRAF(V600E) mutation compared to treatments with IgG control or a BRAF inhibitor,<br>dabrafenib. Finally, we describe a 3D1-based ELISA for the detection of Nodal in<br>serum samples from cancer patients. These data suggest the potential of 3D1 mAb<br>for selecting and targeting Nodal expressing cancers.<br>
Schutz K, Alecsandru D, Grimbacher B, Haddock J, Bruining A, Driessen G, De Vries E, Van Hagen PM, Hartmann I, Fraioli F, Milito C, Mitrevski M, Quinti I, Serra G, Kelleher P, Loebinger M, Litzman J, Postranecka V, Thon V, Babar J, Condliffe AM, Exley A, Kumararatne D, Screaton N, Jones A, Bondioni MP, Lougaris V, Plebani A, Soresina A, Sirignano C, Spadaro G, Galal N, Gonzalez-granado LI, Dettmer S, Stirling R, Chapel H, Lucas M, Patel S, Farber CM, Meyts I, Banerjee AK, Hackett S, Hurst JR, Warnatz K, Gathmann B, Baumann U * Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group(8 visite) J Clin Immunol (ISSN: 0271-9142linking, 1573-2592), 2018 Dec 13; N/D: N/D-N/D. Impact Factor:2.654 DettagliEsporta in BibTeXEsporta in EndNote
94 Records (89 escludendo Abstract e Conferenze). Impact factor totale: 301.532 (290.158 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 325.871 (310.592 escludendo Abstract e Conferenze).